Development of a disability scale for myotonic dystrophy type 1

Area of Science:

• Neurology
• Clinical Assessment
• Disease Measurement

Background:

• Myotonic dystrophy type 1 (DM1) is a complex multisystem disorder.
• Existing assessments often focus narrowly on muscular impairment, lacking comprehensive neurological feature quantification.
• A need exists for a holistic tool to evaluate DM1 patient status.

Purpose of the Study:

• To develop and validate a novel functional scale for DM1 patients.
• The scale aims to quantify neuromuscular impairment (NI) and disability.
• To provide a comprehensive measure of DM1's diverse neurological manifestations.

Main Methods:

• A 21-item ordinal scale was developed across four domains: neuropsychology, motricity, myotonia, and daily life activities.
• Reliability (inter/intra-observer), internal consistency, and external validity were assessed.
• Sensitivity to clinical changes after treatment (mexiletine) and over a one-year follow-up was evaluated in 33 DM1 patients.

Main Results:

• The scale demonstrated excellent inter-observer agreement (ICC=0.72-0.97) and high internal consistency (Cronbach's α > 0.73).
• Total and sub-scores correlated significantly with objective measures, disease duration, and multisystem involvement.
• The scale detected significant improvements in myotonia post-treatment and significant worsening in other areas over time in untreated patients.

Conclusions:

• The developed scale offers a practical and reliable method for assessing NI and disability in DM1.
• This tool can aid clinicians in monitoring disease progression and treatment efficacy.
• Further long-term studies are recommended to solidify its utility in tracking DM1 severity.